Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation a rabbit model of electrically induced carotid artery thrombosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 1, 2000, Pages 212-218

  Wong, Pancras C ^a   Crain, Earl J ^a   Knabb, Robert M ^a   Meade, Raymond P ^a   Quan, Mimi L ^a   Watson, Carol A ^a   Wexler, Ruth R ^a   Wright, Matthew R ^a,b   Slee, Andrew M ^a  

^a DUPONT COMPANY   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; 5 ISOXAZOLECARBOXAMIDE, 3 [3 (AMINOIMINOMETHYL)PHENYL] N 5 [2' (AMINOSULFONYL) [1,1' BIPHENYL] 4 YL] 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) TRIFLUOROACETIC ACID; ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; ISOXAZOLE DERIVATIVE; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; ELECTROSTIMULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ASPIRIN; BLOOD PRESSURE; BORON COMPOUNDS; CAROTID ARTERY THROMBOSIS; FACTOR XA; FIBRINOLYTIC AGENTS; HEART RATE; HEPARIN; HUMANS; ISOXAZOLES; MALE; MICROSCOPY, ELECTRON, SCANNING; OLIGOPEPTIDES; PLATELET AGGREGATION; RABBITS; RECOMBINANT PROTEINS; TETRAZOLES;

EID: 0033810831     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Models to study thrombotic disorders
2. New insights into how blood clots: Implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy
3. Effect of various antiplatelet agents on acute arterial thrombosis in the rat
4. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator
5. Anticoagulants: Thrombin and factor Xa inhibitors
6. A highly reproducible model of arterial thrombosis in rats
7. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor
8. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation
9. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside
10. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis
11. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase
12. The emerging role of low-molecular-weight heparin in cardiovascular medicine
13. Experimental arterial thrombosis in rats with continuous registration
14. Thrombin and factor Xa inhibitors
15. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis
16. The selective inhibition of thrombin by peptides of boroarginine
17. Laboratory assessment of antithrombotic therapy: What tests and if so why?
18. In vivo characterization of a new synthetic thrombin inhibitor
19. Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa
20. Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis
21. Characterization of recombinant tick anticoagulant peptide
22. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries
23. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2
24. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1
25. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats
26. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis
27. Synthetic inhibitors of coagulation factor Xa
28. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa
29. Protection of factor Xa from neutralization by the heparin-antithrombin complex
30. Pharmacology of the low-molecular-weight heparins
31. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
32. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis
33. Nonpeptide factor Xa inhibitors I. Studies with SF303 and SK549, a new class of potent antithrombotics